| Autor: |
Castro-Alonso FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, Bourlon MT |
| Jazyk: |
angličtina |
| Zdroj: |
Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2023 Jun 12; Vol. 37 (6), pp. 256-261. |
| DOI: |
10.46883/2023.25920998 |
| Abstrakt: |
A Hispanic man, aged 42 years, was diagnosed with stage IV metastatic urothelial bladder cancer (MUBC) with nonregional lymphadenopathies and lung, bone, and skin involvement. He received first-line treatment with gemcitabine and cisplatin for 6 cycles, achieving a partial response (PR). Next, he received immunotherapy maintenance with avelumab for 4 months until disease progression. A next-generation sequencing test of paraffin-embedded tumor tissue identified a fibroblast growth factor receptor 3 (FGFR3) S249C missense mutation. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
